GPLD1 Antibody - #DF9750

Fig. 2. Gpld1 enhances IFN-I antiviral immunity in response to viral infection. (A to C) RT-qPCR analysis of Ifnβ mRNA in HEK293T cells transfected with control vectors (Ctrl) or GFP-Gpld1, and then infected with Sendai virus (SeV) [multiplicity of infection (MOI) = 1.0] as indicated (A), or infected with SeV (MOI = 1.0 and 3.0; 12 hours) (B), or transfected with control shRNAs (shCtrl) or shGpld1 (1# or 2#) then infected with SeV (MOI = 1.0; 12 hours) (C). (D) RT-qPCR analysis of Viperin mRNA in HEK293T cells transfected with control vectors or GFP-Gpld1, and then infected with SeV as (C). (E) Fluorescence microscopy of the VSV virus with a GFP gene (VSV-GFP) in HepG2 cells transfected with control vectors or Flag-Gpld1, and then infected with VSV (MOI = 1.0) for 24 hours. Scale bars, 100 μm. (F) Western blot analysis of VSV-encoded G protein (VSV-G) in HepG2 cells transfected with increasing amounts of Flag-Gpld1, and then infected with VSV as (E). IB, immunoblot. (G) Western blot analysis of VSV-G in HepG2 cells transfected with shGpld1 (1# or 2#), and then infected with VSV-GFP (MOI = 1.0) for 24 hours. (H) RT-qPCR analysis of virus RNA levels in HEK293T cells transfected with Flag-Gpld1, and then infected with VSV/H1N1/HSV-1 (MOI = 1.0) for 24 hours. (I) RT-qPCR analysis of HBV RNA levels in HepG2 cells cotransfected with HBV-1.3 constructs and Flag-Gpld1. (J and K) RT-qPCR analysis of mIfnβ mRNA levels in Gpld1+/+ or Gpld1−/− mouse primary hepatocytes (J) or mouse bone marrow cells (K) infected with VSV (MOI = 1.0) for 12 hours. (L) Tissue culture-infective dose (TCID50) assay of virus titers in culture supernatants from (J). *P < 0.05, **P < 0.01, and ***P < 0.001 (two-tailed unpaired Student’s t test). Data are shown as mean and SD of three biological replicates [(A) to (D) and (H) to (L)], or are representative of three independent experiments [(F) and (G)].